Third generation dendritic cell vaccines for tumor immunotherapy

European Journal of Cell Biology

Volumn 91, Issue 1, 2012, Pages 53-58

  Frankenberger, Bernhard ^a   Schendel, Dolores J ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Antitumor response; Dendritic cell maturation; Dendritic cell based vaccines; Dendritic cells; Memory effector cytotoxic T lymphocytes; Th1 polarization; Young dendritic cells

Indexed keywords

DENDRITIC CELL VACCINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG ACTIVITY; HUMAN; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; TH1 CELL;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-12; KILLER CELLS, NATURAL; NEOPLASMS; RNA, NEOPLASM; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TOLL-LIKE RECEPTORS; TRANSFECTION;

EID: 84855961831     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2011.01.012     Document Type: Short Survey

References (53)

1. Ashley D.M., Faiola B., Nair S., Hale L.P., Bigner D.D., Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 1997, 186:1177-1182.
2. Boczkowski D., Nair S.K., Snyder D., Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996, 184:465-472.
3. Boczkowski D., Nair S.K., Nam J.H., Lyerly H.K., Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000, 60:1028-1034.
4. Bürdek M., Spranger S., Wilde S., Frankenberger B., Schendel D.J., Geiger C. Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J. Transl. Med. 2010, 8:90.
5. Cerundolo V., Hermans I.F., Salio M. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 2004, 5:7-10.
6. Coulie P.G., van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 2003, 15(2):131-137.
7. Dauer M., Obermaier B., Herten J., Haerle C., Pohl K., Rothenfusser S., Schnurr M., Endres S., Eigler A. Mature dendritic cells derived from human monocytes within 48hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 2003, 170:4069-4076.
8. Dauer M., Schad K., Herten J., Junkmann J., Bauer C., Kiefl R., Endres S., Eigler A. FastDC derived from human monocytes within 48h effectively prime tumor antigen-specific cytotoxic T cells. J. Immunol. Methods 2005, 302:145-155.
9. Dauer M., Lam V., Arnold H., Junkmann J., Kiefl R.C., Bauer C., Schnurr M., Endres S., Eigler A. Combined use of Toll-like receptor agonists and prostaglandin E2 in the FastDC model: rapid generation of human monocyte derived dendritic cells capable of migration and IL-12p70 production. J. Immunol. Methods 2008, 337:97-105.
10. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
11. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., Trinchieri G., Caux C., Garrone P. A type I interferon autocrineparacrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 2005, 201:1435-1446.
12. Geiger C., Noessner E., Frankenberger B., Falk C.S., Pohla H., Schendel D.J. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J. Mol. Med. 2009, 87(June (6)):595-612.
13. Gilboa E., Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 2004, 199:251-263. Review.
14. Goff S.L., Smith F.O., Klapper J.A., Sherry R., Wunderlich J.R., Steinberg S.M., White D., Rosenberg S.A., Dudley M.E., Yang J.C. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother. 2010, 33(8):840-847.
15. Gorden K.B., Gorski K.S., Gibson V.R., Kedl M., Kieper W.C., Qiu X., Tomai M.A., Alkan S.S., Vasilakos J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 2005, 174:1259-1268.
16. Heiser A., Maurice M.A., Yancey D.R., Coleman D.M., Dahm P., Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001, 61:3388-3393.
17. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 2002, 109:409-417.
18. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3:196-200.
19. Ito T., Amakawa R., Fukuhara S. Roles of Toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Hum. Immunol. 2002, 63:1120-1125.
20. Jager E., Jager D., Knuth A. Clinical cancer vaccine trials. Curr. Opin. Immunol. 2002, 14:178-182.
21. Jarnjak-Jankovic S., Hammerstad H., Saeboe-Larssen S., Kvalheim G., Gaudernack G. A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 2007, 7:119.
22. Javorovic M., Pohla H., Frankenberger B., Wölfel T., Schendel D.J. RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol. Ther. 2005, 12(4):734-743.
23. Javorovic M., Wilde S., Zobywalski A., Noessner E., Lennerz V., Wölfel T., Schendel D.J. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J. Immunother. 2008, 31(1):52-62.
24. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serumfree conditions. Eur. J. Immunol. 1997, 27:3135-3142.
25. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002, 3:499.
26. Kaisho T., Tanaka T. Turning NF-kappaB and IRFs on and off in DC. Trends Immunol. 2008, 29(7):329-336.
27. Kyte J.A., Kvalheim G., Lislerud K., thor Straten P., Dueland S., Aamdal S., Gaudernack G. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol. Immunother. 2007, 56(5):659-675.
28. Larangé A., Antonios D., Pallardy M., Kerdine-Romer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J. Leukoc. Biol. 2009, 85:673-683.
29. Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W., Schendel D.J. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 2010, 120(11):3869-3877.
30. Liu J., Hamrouni A., Wolowiec D., Coiteux V., Kuliczkowski K., Hetuin D., Saudemont A., Quesnel B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-g and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
31. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens M., Kapsenberg M.L., Kirkwood J.M., Storkus W.J., Kalinski P. a-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL inducing activity. Cancer Res. 2004, 64:5934-5937.
32. Milazzo C., Reichardt V.L., Muller M.R., Grünebach F., Brossart P. Induction of myeloma specific cytotoxic T cells using dendritic cells transfected with tumor derived RNA. Blood 2003, 101:977-982.
33. Muller M.R., Grunebach F., Nencioni A., Brossart P. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J. Immunol. 2003, 170:5892-5896.
34. Mumberg D., Wick M., Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin. Immunol. 1996, 8:289-293.
35. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6:769-776.
36. Obermaier B., Dauer M., Herten J., Schad K., Endres S., Eigler A. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol. Proc. Online 2003, 5:197-203.
37. Palucka K., Ueno H., Zurawski G., Fay J., Banchereau J. Building on dendritic cell subsets to improve cancer vaccines. Curr. Opin. Immunol. 2010, 22(2):258-263.
38. Philbin V.J., Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem. Soc. Trans. 2007, 35:1485-1491.
39. Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998, 282:480-483.
40. Roelofs M.F., Joosten L.A., Abdollahi-Roodsaz S., van Lieshout A.W., Sprong T., van den Hoogen F.H., van den Berg W.B., Radstake T.R. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005, 52:2313-2322.
41. Schaft N., Dorrie J., Thumann P., Beck V.E., Müller I., Schultz E.S., Kämpgen E., Dieckmann D., Schuler G. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J. Immunol. 2005, 174:3087-3097.
42. Schendel D.J. Dendritic cell vaccine strategies for renal cell carcinoma. Expert Opin. Biol. Ther. 2007, 7:221-232.
43. Schuler G., Schuler-Thurner B., Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 2003, 15:138-147.
44. Selenko-Gebauer N., Majdic O., Szekeres A., Hofler G., Guthann E., Korthauer U., Zlabinger G., Steinberger P., Pickl W.F., Stockinger H., Knapp W., Stöckl J. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 2003, 170:3637-3644.
45. Sommermeyer D., Neudorfer J., Weinhold M., Leisegang M., Engels B., Noessner E., Heemskerk M.H., Charo J., Schendel D.J., Blankenstein T., Bernhard H., Uckert W. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 2006, 36(11):3052-3059.
46. Spiess P.J., Yang J.C., Rosenberg S.A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst. 1987, 79:1067-1075.
47. Spranger S., Javorovic M., Bürdek M., Wilde S., Mosetter B., Tippmer S., Bigalke I., Geiger C., Schendel D.J., Frankenberger B. Generation of T helper-1 polarizing dendritic cells using the Toll-like receptor 7/8 agonist CL075. J. Immunol. 2010, 185(1):738-747.
48. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., Coleman D., Niedzwiecki D., Gilboa E., Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003, 63:2127-2133.
49. Van Tendeloo V.F., Van de Velde A., Van Driessche A., Cools N., Anguille S., Ladell K., Gostick E., Vermeulen K., Pieters K., Nijs G., Stein B., Smits E.L., Schroyens W.A., Gadisseur A.P., Vrelust I., Jorens P.G., Goossens H., de Vries I.J., Price D.A., Oji Y., Oka Y., Sugiyama H., Berneman Z.N. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(31):13824-13829.
50. Visseren M.J., van Elsas A., van der Voort E.I., Ressing M.E., Kast W.M., Schrier P.I., Melief C.J. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 1995, 154:3991-3998.
51. Wilde S., Sommermeyer D., Frankenberger B., Schiemann M., Milosevic S., Spranger S., Pohla H., Uckert W., Busch D.H., Schendel D.J. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity. Blood 2009, 114(10):2131-2139.
52. Wolfel T., Hauer M., Schneider J., Serrano M., Wölfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Büschenfelde K.H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284.
53. Zobywalski A., Javorovic M., Frankenberger B., Pohla H., Kremmer E., Bigalke I., Schendel D.J. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl. Med. 2007, 5:18-34.